Year: 2022

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.  The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The archived webcast will be available for approximately 30 days following the presentation date. About Axiomer® ProQR is pioneering a next-generation...

WINSTON-SALEM, N.C., Dec. 22, 2022 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare Conference in San Francisco on Wednesday, January 11th, 2023, at 3:45 PM PT. A webcast of the presentation will be available on the Events and Presentations section of ProKidney’s investor relations website at https://investors.prokidney.com/news-events/events-and-presentations. Investors attending the conference who are interested in meeting with ProKidney management may request a meeting by contacting their J.P. Morgan representative, or reaching out to Glenn Schulman at glenn.schulman@prokidney.com or Lee Roth at...

NoHo Partners Plc STOCK EXCHANGE RELEASE 22 DECEMBER 2022 at 12:00 EET The Board of Directors of NoHo Partners Plc has resolved on the fourth earning period of the long-term incentive plan for the company’s key employees NoHo Partners Plc’s Board of Directors has resolved on the fourth earning period of the long-term incentive plan for the company’s key employees. The fourth earning period is 24 months, starting on 1 January 2023, and ending on 31 December 2024. The reward criteria for the fourth earning period are based on NoHo Partners Plc’s profitable growth. There are ten participants in the long-term incentive plan’s fourth earning period. A maximum of 280,420 reward shares could be awarded for the fourth earning period. The value of the maximum reward at the average share price on the trading day preceding this stock...

Share Buyback Transaction Details December 15 – December 21, 2022 December 22, 2022 – Wolters Kluwer (Euronext: WKL), a global leading provider of expert solutions, insights and services for professionals, today reports that it has repurchased 321,695 of its own ordinary shares in the period from December 15, 2022, up to and including December 21, 2022, for €32.6 million and at an average share price of €101.20. These repurchases are part of the share buyback program under which we intend to repurchase shares for €1 billion during 2022, as announced on August 3, 2022. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2022Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2022 to date 9,958,326 983.1 ...

U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023 FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high-concentration of Humira® and confirmed that the data provided are sufficient to support a determination of interchangeability; approval requires satisfactory outcome of upcoming facility reinspection Alvotech is anticipating a facility reinspection by the FDA in the first quarter of 2023Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the FDA has granted a new Biosimilar User Fee Amendment (BsUFA) goal date of April 13, 2023, for Alvotech’s original Biologics License Application...

U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high-concentration of Humira® and confirmed that the data provided are sufficient to support a determination of interchangeability; approval requires satisfactory outcome of upcoming facility reinspectionAlvotech is anticipating a facility reinspection by the FDA in the first quarter of 2023REYKJAVIK, Iceland, Dec. 22, 2022 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the FDA has granted a new Biosimilar User Fee Amendment (BsUFA) goal date of...

Company Announcement No. 1005 At the Extraordinary General Meeting on 22 November 2022, a decision was passed to reduce the share capital by DKK 15,000,000 by cancelling 15,000,000 treasury shares. No objections to the share capital reduction have been received. Thus, registration of the share capital reduction was made by the Danish Business Authority on 22 December 2022. Following the cancellation of the 15,000,000 shares, the share capital of DSV A/S has a current nominal value of DKK 219,000,000 divided into 219,000,000 shares with a face value of DKK 1, corresponding to a total of 219,000,000 voting rights. Any questions may be addressed to Executive Vice President, Investor Relations, Flemming Ole Nielsen, tel. +45 43 20 33 92. Yours sincerely,DSV A/SAttachment1005 – Announcement (22.12.2022) – Reduction...

Uponor Corporation, Stock Exchange Release, 22 December 2022 at 11:16 am EET Uponor Corporation: Flagging notification – Shareholding of Oras Invest in Uponor has gone above the threshold of 25 per cent This is a notification in accordance with Chapter 9, Section 10 of the Finnish Securities Market Act. Uponor Corporation has on 22 December 2022 received a notification of a change in shareholding in accordance with Chapter 9, Section 5 of the Securities Market Act. According to the notification, holdings of Oras Invest Ltd in shares of Uponor Corporation on 21 December 2022 has gone above the threshold of 25% and is 18,322,159 shares representing 25.03% of the share capital and votes in the company. The share capital of Uponor Corporation consists of 73,206,944 shares and each share is entitled to one vote at the general meeting...

On 21 December 2022 the merger of Coop Pank AS (Coop Pank) and CP Varad AS was entered into the Estonian Commercial Register. With the entry, the merger has been completed. As a result of the merger, Coop Pank is the legal successor of CP Varad AS and CP Varad AS was deleted from the Estonian Commercial Registry. With registration of the merger in the Estonian Commercial Registry, all the assets, rights and obligations of CP Varad AS were transferred to Coop Pank. The balance sheet date of the merger was 1 July 2022. Since it is an intragroup merger, it does not have an impact on the consolidated financial position and rights and obligations of Coop Pank’s group. Earlier information announced by Coop Pank about the merger is available here and here. Additional information:Paavo TruuCFOPhone: +372 5160 231E-mail: paavo.truu@cooppank.ee Coop...

Uponor Corporation, Managers’ transactions, 22 December 2022 at 11:15 am EET Uponor Corporation: Managers’ transactions – Oras Invest has acquired 60,000 Uponor shares With reference to the EU Market Abuse Regulation, Uponor has received a notification from Oras Invest Oy of transactions made on 21 December 2022 with its financial instrument. Detailed information about the transaction is given below. Person subject to the notification requirementName: Oras Invest OyPosition: Closely associated personIssuer: Uponor OyjLEI: 743700KA2GMSYJM3CM12Notification type: INITIAL NOTIFICATION Person discharging managerial responsibilities in issuerName: Paasikivi, AnnikaPosition: Member of the Board____________________________________________ Transaction date: 2022-12-21Instrument type: SHAREISIN: FI0009002158Nature of the transaction: ACQUISITION Volume:...